Visiopharm and Hamamatsu Announce Worldwide OEM Agreement and Reseller Partnership for Quantitative Digital Pathology
Hoersholm, Denmark (PRWEB) April 16, 2012
April 16, 2012 - Visiopharm, a leading provider of Quantitative Digital Pathology solutions, and Hamamatsu, a leading provider of whole slide scanners and data management solutions for digital pathology, announce today a non-exclusive worldwide original equipment manufacturer (OEM) agreement and reseller partnership for Visiopharm’s Quantitative Digital Pathology (QDP) solutions. Under the partnership Visiopharm will be an OEM for Hamamatsu’s new NDP.Analyze software, a research tool for tissue image analysis, which is fully compatible with Visiopharm’s entire suite of QDP solutions. Hamamatsu will market and sell the entire suite of QDP solutions, including CloudAnalysis, DeployedAnalysis, Stereology, and Application Protocol Packages (APPs) from Visiopharm’s new APPCenter.
The NDP.Analyze will be exhibited at the Analytica on April 17-20 2012, in Munich, Germany.
Hamamatsu, who is known throughout the world for their NanoZoomer Digital Pathology (NDP) whole slide scanners, will expand their offering in digital pathology to include quantitative digital pathology. The full range of analysis solutions are integrated with the NDP.Serve data management software. The software will be available directly from Hamamatsu Worldwide.
Masafumi Oshiro, Product manager of Hamamatsu Photonics, stated “Hamamatsu is committed to provide complete solutions of high quality to its customers. Image analysis is becoming an increasingly important part of Digital Pathology. With the NDP.analyze and the software from Visiopharm fully integrated in the NDP environment, we are now able to provide a powerful image analysis solution. That scales well across the needs from individual academic researchers to large pharmaceutical companies with a regular and high-volume need for analysis. We are pleased to be able to offer image analysis APPs that provide a risk-free approach to image analysis for our customers, and at the same time provide immediate productivity with a very low learning curve.
NDP.Analyze integrated with Visiopharm’s innovative solutions for QDP, will provide Hamamatsu customers with leading technology and flexible options, including analysis of NanoZoomer whole slide images in the Cloud and unlimited access to Visiopharm’s patent-pending APPCenter. The APPCenter will provide both new and current NanoZoomer and Visiopharm customers with innovative, affordable options for their deployed solutions, but also allow them to expand their efforts to collaborate and share data in the Cloud.
Cloud analysis is an easy to budget solution for Hamamatsu customers who need access to sophisticated image analysis capabilities for a specific project which is limited in time. Whether it is for a week, a month, or longer customers will only pay for analysis when they need it. Hamamatsu customers can now have instant access, and be able to analyze whole slide images from work, home, or from anywhere.
Michael Grunkin PhD, CEO of Visiopharm, stated “We are very impressed with Hamamatsu and their innovative vision for digital pathology. The NanoZoomer is a very robust product capable of providing scanned images of a consistent high quality and with a very competitive scan speed. It is clear to us that Hamamatsu will play an important role in providing integrated and complete quality solutions to the research market. An OEM agreement and reseller partnership with Hamamatsu will expand the availability of Visiopharm’s QDP solutions worldwide, and enable the rapidly growing digital pathology market to work in an efficient, integrated digital workflow with Hamamatsu’s NanoZoomer Digital Pathology solutions.
Over the past 10 years, Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, clinical researchers, and academic researchers all over the world. Visiopharm has more than 300 deployed systems worldwide and a large network of distribution and support partners, and is featured in over 400 scientific publications.
Hamamatsu Photonics is a world-leading manufacturer of opto-electronic components and systems and employs over 4000 staff worldwide. The corporate headquarters are based in Hamamatsu City, Japan along with six manufacturing plants and central research laboratories. Since its inception in 1953, Hamamatsu Photonics has expanded to now enjoy a global presence with production facilities, business locations and associated companies throughout Asia, Europe and North America.
Hamamatsu Photonics’ corporate philosophy stresses the advancement of Photonics through extensive research and development. The component- and system-products such as photosensors, cameras, complex systems are widely used in different research fields like communication, biomedical science, material science, pharmacology, medical science and many others.